Roquefort Therapeutics (LON:COIL) Stock Price Up 0.5% – Should You Buy?

Posted by Donna Armstrong on Oct 14th, 2026

Roquefort Therapeutics plc (LON:COIL – Get Free Report) shares traded up 0.5% during trading on Monday. The stock traded as high as GBX 6.85 and last traded at GBX 6.25. 6,342,298 shares were traded during mid-day trading, an increase of 2,314% from the average daily volume of 262,781 shares. The stock had previously closed at GBX 6.22.

Wall Street Analysts Forecast Growth

Separately, Shore Capital Group reiterated a “house stock” rating on shares of Roquefort Therapeutics in a research report on Monday, September 21st.

Get Our Latest Report on COIL

Roquefort Therapeutics Stock Down 2.8%

The company’s 50 day moving average price is GBX 8.27 and its two-hundred day moving average price is GBX 9.06. The firm has a market cap of £28.00 million, a PE ratio of -0.32 and a beta of 0.05. The company has a current ratio of 0.63, a quick ratio of 3.07 and a debt-to-equity ratio of 8.18.

Roquefort Therapeutics (LON:COIL – Get Free Report) last issued its quarterly earnings data on Monday, September 28th. The company reported GBX (1.66) earnings per share (EPS) for the quarter. Roquefort Therapeutics had a negative net margin of 57,057.07% and a negative return on equity of 18.71%.

Insiders Place Their Bets

In related news, insider Stephen Paul West bought 270,306 shares of the stock in a transaction that occurred on Monday, September 28th. The shares were bought at an average cost of GBX 7 per share, for a total transaction of £18,921.42. Company insiders own 36.27% of the company’s stock.

Roquefort Therapeutics Company Profile

(Get Free Report)

Coiled Therapeutics (AIM: COIL) is an AIM-listed, clinical-stage biotechnology company focused on developing innovative precision oncology therapies. Its lead programme, AO-252, is a novel TACC3 inhibitor currently in Phase I clinical trials in the USA (trials ID: NCT06136884). Coiled Therapeutics is actively enrolling patients to test for safety and efficacy in patients whose cancer has progressed on other treatments. The Company is also assessing its STAT-6 siRNA programme for immunology indications.